Transgene

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.

Beleggen met ongekend lage tarieven?
Aandelen BE/NL €2+0,03% / VS €0,50+$0,004 p/st
Kernselectie: Geen kosten turbo's, ETF's en fondsen
DEGIRO: meer informatie / rekening openen


mongoose
Forum actieveling
Forum actieveling
Berichten: 318
Lid geworden op: 22 nov 2016 15:01
waarderingen: 182
Contacteer:

Re: Transgene

Bericht door mongoose »

And its gone! schreef:
13 jan 2021 09:24
rustige stijging, maar de trend zet zich door.
Na een half uur zitten we al aan het dagelijks gemiddeld volume!
Zien we de 2€ vandaag? :up:
Gisteren stond er een verkoopblok van 95.000 stuks, en dat verdween vlot. Redelijk verbazend voor dit aandeel.







Volg Beursig.com op Twitter en Facebook


Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

mongoose schreef:
13 jan 2021 09:43
And its gone! schreef:
13 jan 2021 09:24
rustige stijging, maar de trend zet zich door.
Na een half uur zitten we al aan het dagelijks gemiddeld volume!
Zien we de 2€ vandaag? :up:
Gisteren stond er een verkoopblok van 95.000 stuks, en dat verdween vlot. Redelijk verbazend voor dit aandeel.
Spelletjes, dat soort orders wordt vaak ingetrokken naarmate de koers nadert.
Iemand wil ze goedkoop inslaan.
NewB76 liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

TRANSGENE (TNG)
Chemical/Pharmaceutical/Health

ISIN: FR0005175080

LAATSTE
(13/01/21 - 10:08)
2,015
WIJZIGING
(0,095)
4,95%
BID
2,005
ASK
2,015
De 2€ staat op het bord, nooit gedacht dit nog te zullen meemaken :D
Straks sta ik nog in het groen (na + 2 jaar)
Gemiddelde 2.46€
NewB76 liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

En we gaan door :wtf:
Na 11 minuten al over de 100K stukjes verhandeld.
TRANSGENE (TNG)
Chemical/Pharmaceutical/Health

ISIN: FR0005175080

LAATSTE
(14/01/21 - 09:06)
2,21
WIJZIGING
(0,16)
Nog altijd geen nieuws... Toch merkwaardige en significante stijging.

efkes speculeren:

-Zou AZN een optie lichten op 1 vd virussen?
- lijkt me sterk dat dit over de eerste dosing gaat van BT-001...

Iemand nog ideeën?

mongoose
Forum actieveling
Forum actieveling
Berichten: 318
Lid geworden op: 22 nov 2016 15:01
waarderingen: 182
Contacteer:

Re: Transgene

Bericht door mongoose »

Terugkerend op het Boursig forum wordt er gesproken over een reeks gesprekken met mogelijke investeerders. Maar een officiële versie heb ik er nog niet van gevonden.

manu47
Premiummember
Premiummember
Berichten: 148
Lid geworden op: 11 apr 2013 13:35
waarderingen: 48
Contacteer:

Re: Transgene

Bericht door manu47 »

Dit misschien?

Oncolytic Virus Therapy Market is Thriving with Rising Latest Trends by 2027 | Top Players- Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax
Photo of tanmay tanmayJanuary 14, 2021 3
The report discusses many vital industry facets that influence Global Oncolytic Virus Therapy industry acutely which includes extensive study of competitive edge, latest technological advancements, region-wise industry environment, contemporary market and manufacturing trends, leading market contenders, and current consumption tendency of the end user. The report also oversees market size, market share, growth rate, revenue, and CAGR reported previously along with its forecast estimation.

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasnt until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

In 2018, the global Oncolytic Virus Therapy market size was 2 million US$ and it is expected to reach 14 million US$ by the end of 2025, with a CAGR of 24.9% during 2019-2025.

Get Sample Copy of The Report NOW!

https://www.marketinsightsreports.com/r ... zy&Mode=21

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasnt until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Oncolytic Virus Therapy Market Segmentation:
Top leading Manufactures Profiled in Oncolytic Virus Therapy Market Report are:

Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, Genelux Corporation, Vyriad, TILT Biotherapeutics, Cold Genesys

Market Research Study Focus on these Types:

HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vaccinia Virus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses

Market Research Study Focus on these Applications:
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Others

Inquire for Discount of Oncolytic Virus Therapy Market Report at:

https://www.marketinsightsreports.com/r ... zy&Mode=21

The report highlights major developments and changing trends adopted by key companies over a period of time. For a stronger and more stable business outlook, the report on the global market carries key projections that can be practically studied.

Oncolytic Virus Therapy Market analysis report has recently added by Research which helps to make informed business decisions. This research report further identifies the market segmentation along with their sub-types. The Oncolytic Virus Therapy Market is expected to reach at a huge CAGR during the forecast period. Various factors are responsible for the market’s growth, which are studied in detail in this research report.

Oncolytic Virus Therapy Market Scenario:
This research report represents a 360-degree overview of the competitive landscape of the Oncolytic Virus Therapy Market. Furthermore, it offers massive data relating to recent trends, technological advancements, tools, and methodologies. The research report analyzes the Oncolytic Virus Therapy Market in a detailed and concise manner for better insights into the businesses.

Report evaluates the growth rate and the Market value based on Market dynamics, growth inducing factors. The complete knowledge is based on latest industry news, opportunities and trends. The report contains a comprehensive Market analysis and vendor landscape in addition to a SWOT analysis of the key vendors.

The key insights of the Oncolytic Virus Therapy Market report:
─The report provides key statistics on the market status of the Oncolytic Virus Therapy market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

─The report provides a basic overview of the industry including its definition, applications and manufacturing technology.

─The Oncolytic Virus Therapy market report presents the company profile, product specifications, capacity, production value, and 2014-2020 market shares for key vendors.

─The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

─The report estimates 2020-2026 market development trends of Oncolytic Virus Therapy Market.

─Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out

─The report makes some important proposals for a new project of Oncolytic Virus Therapy Industry before evaluating its feasibility.

The research includes historic data from 2015 to 2020 and forecasts until 2026 which makes the report an invaluable resource for company executives, marketing executive, sales and product managers, consultants, analysts, and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.

In conclusion, Oncolytic Virus Therapy market report presents the descriptive analysis of the parent market supported elite players, present, past and artistic movement information which is able to function a profitable guide for all the Oncolytic Virus Therapy Industry business competitors. Our expert research analyst’s team has been trained to provide in-depth market research report from every individual sector which will be helpful to understand the industry data in the most precise way.

Contact US:

Irfan Tamboli (Head of Sales) – Market Insights Reports

Phone: + 1704 266 3234

Mob: +91-750-707-8687

sales@marketinsightsreports.com

irfan@marketinsightsreports.com
And its gone! liked last!
C50, IWDA, CP9, CJ1, Ontex, Mytilineos, EVS, Moury Construct, CK Asset Holding, NN, Nationale Bank, FNG, NEL ASA, Innate Pharma, Kiadis, Biocartis, KKO, Exmar, Acacia Pharma, Transgene, Pharming, Galapagos, Celyad, Smartphoto, Orange Belgium, iA Financial, Econocom

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene, Bioinvent Get ANSM Approval For Phase I/IIa Trial
07:39 (19/01) - Bron: Reuters
Jan 19 (Reuters) - BioInvent International AB :
* TRANSGENE AND BIOINVENT RECEIVE APPROVAL FROM ANSM TO
PROCEED
WITH PHASE I/IIA TRIAL OF ANTI-CTLA4-ARMED ONCOLYTIC VIRUS
BT-001 IN SOLID TUMORS
* FIRST PATIENT IS EXPECTED TO BE ENROLLED IN THIS TRIAL IN
UPCOMING WEEKS

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
NewB76 liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene: First Head & Neck Cancer Patient Treated In France In Phase I Trial With TG4050
07:43 (21/01) - Bron: Reuters
Jan 21 (Reuters) - TRANSGENE SA :
* FIRST HEAD & NECK CANCER PATIENT TREATED IN FRANCE IN A
PHASE I
TRIAL WITH TG4050 (MYVAC® PLATFORM), TRANSGENE’S INNOVATIVE
INDIVIDUALIZED IMMUNOTHERAPY
* COMBINES TRANSGENE'S EXPERTISE IN VIRUS-BASED
IMMUNOTHERAPIES,
NEC'S LONGSTANDING AI TECHNOLOGIES AND COMMITMENT OF PRESTIGIOUS
CANCER CARE CENTERS
* FIRST DATA FROM TWO TRIALS EVALUATING TG4050 ARE EXPECTED
IN 2H
2021

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
mongoose liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

Jepla we staan positief sinds aug 2019, nooit gedacht dit te zullen meemaken.
Denk dat ik ze nog even ga houden, kijken waar dit naar toe gaat (hopelijk geen kapitaalverhoging)

manu47
Premiummember
Premiummember
Berichten: 148
Lid geworden op: 11 apr 2013 13:35
waarderingen: 48
Contacteer:

Re: Transgene

Bericht door manu47 »

Ik nog 10% te gaan tot break even. Ook nooit gedacht dat ik hier nog ging geraken :) . Hopelijk geraak ik daar en dan stop loss en buiten.
C50, IWDA, CP9, CJ1, Ontex, Mytilineos, EVS, Moury Construct, CK Asset Holding, NN, Nationale Bank, FNG, NEL ASA, Innate Pharma, Kiadis, Biocartis, KKO, Exmar, Acacia Pharma, Transgene, Pharming, Galapagos, Celyad, Smartphoto, Orange Belgium, iA Financial, Econocom


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie